|
|
 |
|
Viewing report
|
|
|
|
Schering-Plough: Pipeline - Products - Performance - Potential
Espicom Business Intelligence Ltd, Aug 2008, Pages: 164
Schering-Plough is a global research-based healthcare company with leading prescription, consumer and animal health products. Schering-Plough is based in New Jersey in the US, and currently has business operations in more than 120 countries outside of the US.
Schering-Plough’s solid performance in the short- to medium-term will depend on the strength of its product portfolio. Remicade, Nasonex/Asmanex, Avelox and PEG-Intron are all forecast to demonstrate sustained growth into fiscal 2012, offsetting any losses predicted in other major products. Furthermore, Zetia and Vytorin, the key components of the Schering-Plough/Merck & Co cholesterol joint venture, will make an increasingly strong contribution to pharmaceutical revenue. In addition, Schering-Plough has historically sought regulatory approval to switch prescription products to OTC status as a means of extending a product’s life-cycle. This strategy has most recently been demonstrated with Claritin and MiraLAX, both of which made a successful transition to the OTC market.
Longer-term growth will be determined by the success of Schering-Plough’s R&D activities. The company’s pipeline is relatively limited in terms of novel candidate products, however, golimumab, SCH 503034, vicriviroc and SCH 530348 have demonstrated promise in their respective indications and could form the basis of Schering-Plough’s product portfolio in the future. R&D expenditure increased by 33.7 per cent in 2007, and the company has intimated investment in research is likely to increase in coming years due to the progression of the early-stage pipeline, increased clinical activity and the addition of projects from the acquisition of Organon BioSciences.
In recent years, Schering-Plough’s manufacturing activities have been severely hampered by a consent decree agreement with the FDA. Originally signed in 2002, the consent decree placed controls on the manufacturing and release of products from the company’s US and Puerto Rican sites, resulting in higher production costs and reduced output. In January 2006, Schering-Plough announced that it had completed all targets set by the decree, and hopes to resume normal operations shortly. In addition, Schering-Plough has streamlined its global supply chain, with savings of approximately US$100 million in 2007. These developments should provide Schering-Plough with a more stable and efficient infrastructure with which to maximise the value of its product portfolio and maintain the growth realised in 2007.
This new strategic analysis report Schering-Plough: Pipeline - Products - Performance - Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. 4D Pharma reports are updated with the latest data on a continuing basis and the full report is released quarterly. Once a year the report undergoes a major review in line with the company's year end. Buyers of the print/pdf editions will receive the latest version and quarterly updated reports for a year. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
|
|
|
|
